The prices of essential medicines may drop, as the National Pharmaceutical Pricing Authority (NPPA) has made significant changes in its norms to rationalise price approvals.
Orders surprise inspections at chemists and pharma stores.
CCI, sector regulators may consult each other if jurisdictions overlap
Moolchand Healthcare Pvt Ltd, the corporate entity formed by the group in 2006 with expansion in mind, is on an acquisition spree for hospital chains, IVF (in vitro fertilisation) clinics and pathological laboratories.
This helps consumers check the authenticity of drugs simply by sending SMSes.
Financial pressure on the parent company triggered the move.
Import alert on unit-6 facility might be lifted by FDA by Sept.
Reebok's staff to get voluntary retirement option, stores may be reduced by a third.
Drug maker Cipla Ltd is rejigging its China business. The pharma company recently exited a significant part of its investment in its Chinese partner Desano Holdings, while ploughing back a part of the funds into the group's units manufacturing biosimilars and active pharmaceutical ingredients (APIs).
The JPC has completed the process of questioning most of the bureaucrats in the 2G scam investigation
Companies such as Dr Reddy's Laboratories, Sun Pharmaceutical, Lupin and Ranbaxy striving to capitalise on opportunities created by pro-generic health care reforms in the US market are facing pricing pressure as the health care supply chain is undergoing consolidation.
Companies say they follow global standards in India as well
In a major relaxation of foreign investment rules in the pharma sector, a special group set up under the finance ministry has suggested it could consider permitting up to 49 per cent FDI (foreign direct investment) in the automatic route for brownfield investments in case the company's control remained in Indian hands.
This move could cost $299 million a year for Indian pharma players.
The upside for Ranbaxy Laboratories is likely to continue even as it loses its 180 days of marketing exclusivity for the Lipitor generic in the American market.
Parliament's standing committee on finance, headed by Bharatiya Janata Party leader Yashwant Sinha, on Thursday finalised its report on the Companies Bill, 2011.
Both the units were under the scanner of FDA since 2011.
Decision on probing the role of auditors will be taken after initial inquiry
The investigative arm of corporate affairs ministry says there may also be involvement of others in alleged fraud, besides top executives.
Budget silent on issue, major decisions unlikely before 2014 election.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances